CODX
Closed
Co-diagnostics Inc
0.278
-0.002 (-0.71%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 0.2802
Day's Range: 0.2702 - 0.3
Send
sign up or login to leave a comment!
When Written:
1.48
Co-Diagnostics Inc is a publicly traded company that specializes in developing and manufacturing molecular diagnostic tests for infectious diseases and other conditions. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
Co-Diagnostics' proprietary technology, called CoPrimer, is a patented platform that allows for highly specific and sensitive detection of genetic material. The company's tests are designed to be easy to use and require minimal training, making them suitable for use in a variety of settings, including hospitals, clinics, and laboratories.
Co-Diagnostics' products include tests for COVID-19, tuberculosis, Zika virus, and other infectious diseases. The company has received regulatory approvals for its tests from the US Food and Drug Administration (FDA), the European Union, and other regulatory agencies around the world.
In addition to its diagnostic products, Co-Diagnostics also offers contract research and development services to other companies in the molecular diagnostics industry. The company has partnerships with several major players in the industry, including Thermo Fisher Scientific and Synbiotics.
As of 2021, Co-Diagnostics has a market capitalization of over $300 million and is traded on the Nasdaq stock exchange under the ticker symbol CODX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Co-Diagnostics' proprietary technology, called CoPrimer, is a patented platform that allows for highly specific and sensitive detection of genetic material. The company's tests are designed to be easy to use and require minimal training, making them suitable for use in a variety of settings, including hospitals, clinics, and laboratories.
Co-Diagnostics' products include tests for COVID-19, tuberculosis, Zika virus, and other infectious diseases. The company has received regulatory approvals for its tests from the US Food and Drug Administration (FDA), the European Union, and other regulatory agencies around the world.
In addition to its diagnostic products, Co-Diagnostics also offers contract research and development services to other companies in the molecular diagnostics industry. The company has partnerships with several major players in the industry, including Thermo Fisher Scientific and Synbiotics.
As of 2021, Co-Diagnostics has a market capitalization of over $300 million and is traded on the Nasdaq stock exchange under the ticker symbol CODX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!